Transudate microflora in dogs with infected pancreonecrosis and sensitivity to antimicrobials remedies

Abstract

Optimizing the use of antimicrobial agents for acute destructive pancreatitis and pancreonecrosis is an important and far-reaching problem. The lethality, which is often observed in acute destructive pancreatitis and pancreonecrosis in dogs is in most cases caused by toxemia, multiple organ failure and the development of infected pancreonecrosis (complication of "sterile" pancreonecrosis). Infectious complications, including involvement in the pathological process of surrounding tissues (infected pancreonecrosis, infected cysts, peritoneum phlegmon) are observed in most animals with pancreonecrosis. According to existing veterinary medicine tactics for the canine acute destructive pancreatitis and pancreonecrosis treatment, the main focus is on timely diagnosis of infectious complications, however, recently, the priorities of therapy are shifting towards the prevention of translocations of bacteria. The purpose of our study was to determine the microbial composition of pancreatic effusion in case of infected pancreonecrosis, and to justify the feasibility of using antibiotic prophylaxis taking into account the sensitivity of microorganisms. The detected microorganisms exhibited intermediate resistance to piperacillin in combination with tazobactam, tobramycin and sulfamethoxazole. The highest sensitivity is set to colistin sulfate and ciprofloxacin. Infection of the pancreas and surrounding tissues is due to microorganisms of the KES group, and to a lesser extent Enterobacter sakazakii and Escherichia coli. No cases of mono-infection were reported during the study. The most effective means of early prevention of purulent and septic complications in dogs for pancreonecrosis is colistin sulfate and ciprofloxacin, which is confirmed by a test for the sensitivity of the detected microflora. The microflora isolated from hemorrhagic and serous effusions in dogs with pancreonecrosis resistant to gentamicin, doxycycline, levofloxacin and exhibiting intermediate resistance to piperacillin / tazobactam, tobramycin and sulphanilamide – sulfamethoxide.